Perspective Therapeutics’ (CATX) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reissued their buy rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a research report released on Tuesday,Benzinga reports. They currently have a $14.00 price target on the stock.

Several other research analysts also recently issued reports on CATX. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Friday, January 30th. Piper Sandler started coverage on shares of Perspective Therapeutics in a research report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 target price on the stock. UBS Group reissued a “buy” rating and set a $7.00 price target (down from $18.00) on shares of Perspective Therapeutics in a research report on Friday, November 21st. HC Wainwright increased their price objective on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Finally, Truist Financial initiated coverage on Perspective Therapeutics in a report on Monday, November 24th. They set a “buy” rating and a $12.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.13.

Perspective Therapeutics Stock Performance

Shares of NYSEAMERICAN CATX opened at $4.95 on Tuesday. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $6.16. The company has a current ratio of 8.66, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $4.26 and a 200 day moving average price of $3.42.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. The firm had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative return on equity of 40.03% and a negative net margin of 9,841.86%. Research analysts predict that Perspective Therapeutics will post -0.88 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of Perspective Therapeutics by 5.0% in the third quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock valued at $11,792,000 after acquiring an additional 163,532 shares in the last quarter. Avidity Partners Management LP raised its position in Perspective Therapeutics by 7.2% during the fourth quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock valued at $8,830,000 after buying an additional 216,700 shares during the period. Geode Capital Management LLC lifted its position in Perspective Therapeutics by 15.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after buying an additional 188,887 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Perspective Therapeutics in the 4th quarter valued at approximately $3,257,000. Finally, State Street Corp grew its holdings in Perspective Therapeutics by 3.3% during the fourth quarter. State Street Corp now owns 1,141,247 shares of the company’s stock valued at $3,138,000 after purchasing an additional 36,543 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Key Stories Impacting Perspective Therapeutics

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Updated clinical data for the company’s lead radiopharmaceutical, [212Pb]VMT‑α‑NET, was accepted for a poster at the AACR Annual Meeting (April 20). The program’s interim safety and preliminary efficacy signals — no dose‑limiting toxicities reported and 76% of patients in the reported cohort without progression — increase visibility and could support future upside if further data confirm efficacy. Read More.
• Positive Sentiment: BTIG Research reaffirmed a “Buy” rating and a $14 price target, signaling continued institutional confidence from at least one research shop — a supportive note for momentum traders and long-term holders. Read More.
• Positive Sentiment: Recent insider purchases (reported in Quiver) show company insiders adding shares, which can be interpreted as management confidence in the business and pipeline. Read More.
• Neutral Sentiment: RBC cut its price target from $18 to $14 but maintained an “Outperform” rating — a mixed signal (lower upside expectation but continued analyst support). This may temper upside while keeping institutional interest. Read More.
• Negative Sentiment: Recent financial results and the latest quarterly report show continuing operating losses (reported EPS of -$0.51 for the quarter and minimal revenue), a very negative net margin, and elevated cash‑burn risk — factors that increase financing and execution risk until positive clinical proof or clearer commercialization path emerges. Read More.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.